Sanofi, leading in the fight for COVID-19
Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/ 2 study to start in September, followed by a Phase 3 study by the end of 2020. If data are positive, regulatory approval could be achieved by the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year overall.
Sanofi and GSK are committed to making the vaccine available globally
As we are hitting the golden zone in FIB retrace. Im going to put this on watch.
Sanofi and GSK are committed to making the vaccine available globally
As we are hitting the golden zone in FIB retrace. Im going to put this on watch.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.